WLWT: A change in mammography standards could help save lives
A new Food and Drug Administration policy will soon require health care providers to tell women if they have dense breast tissue, a trait that can make cancer harder to detect. The move is aimed to support prevention, early detection and treatment of breast cancer.
The announcement also follows advocacy from patients, lawmakers and University of Cincinnati Cancer Center physicians that led to the passage of Ohio House Bill 371, which requires insurance companies to cover additional screenings for individuals who are at high risk for breast cancer or have dense breast tissue.
Erich J. Boomgarden, MD, assistant professor in UC's College of Medicine and a UC Health radiologist, told WLWT mammography is still the standard of care, but additional MRI or ultrasound screenings can help see through dense breast tissue.
"If you get your screening mammogram, and assuming it comes back negative, meaning there was nothing suspicious in there, we would recommend getting a supplemental screening in six months," Boomgarden said. "We do that because it's helpful for us because again, by staggering it that way, then anything that may be developing, between the screening mammogram and MRI hopefully will be detected sooner then."
Featured photo at top of a 3D mammogram machine. Photo/Colleen Kelley/UC Marketing + Brand.
Related Stories
UC biologist talks about 'pearmageddon'
March 16, 2026
WLWT talks to UC biologist and Department Head Theresa Culley about invasive, nonnative Callery pear trees that are spreading across Ohio forests after they were introduced by landscapers more than 50 years ago.
Local media highlight completion of Blood Cancer Healing Center fourth and fifth floors
March 16, 2026
Local media including WLWT and the Cincinnati Business Courier highlighted the opening of research laboratories and the UC Osher Wellness Suite and Learning Kitchen at the University of Cincinnati Cancer Center’s Blood Cancer Healing Center.
Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy
March 16, 2026
Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.